Abstract:

Aim: was to estimate the diagnostic value of PET with ¹⁸F-Choline and ¹⁸F-FDG in case of mixed hepatocellular (HCC) and cholangiocellular cancer (CCC).

Materials and methods: PET/CT with ¹⁸F-Choline and ¹⁸F-FDG was performed on 70 years old patient, with diagnosed hepatobilliary cancer. CT scan and MRI with intravenous contrast-enhanced, histological and immunohistochemical study of postoperative material (right-sided hemihepatectomy) were also performed.

Results: difference in the accumulation of ¹⁸F-Choline and ¹⁸F-FDG in some areas of mixed hepatocellular and cholangiocellular cancer was detected: in the field of cholangiocellular cancer and ir the field of poorly differentiated hepatocellular cancer.

Conclusions: ¹⁸F-choline has a low diagnostic value in the detection of cholangiocellular cancer and poorly differentiated HCC, in contrast to ¹⁸F-FDG, whereas at high differentiated HCC study, ¹⁸F-choline is more preferable. Diagnostic value of ¹⁸F-FDG at high differentiated HCC is extremely low.

References

1.     Patjutko Ju.I., Sagajdak I.V., Chuchuev E.S. Gepatocelljuljarnyj rak pecheni [Hepatocellular cancer]. Bjulleten' medicinskih internet-konferencij. 2011;1: 35-61 [In Russ].

2.     Chissov V.I. Onkologija [Oncology]. M.: Gjeotar-Media. 2007; 391-399 [In Russ].

3.     Sukonko O.G. Gepatocelljuljarnyj rak. Algoritm diagnostiki i lechenija zlokachestvennyh novoobrazovanij[Hepatocellular cancer. Algorithm of diagnostics and treatment of malignant neoplasms] M.: Media Sfera. 2012; 127-135 [In Russ] .

4.     Bosh F.X., Ribes J., Borras J. Epidemiology of primary liver cancer. Semin. Liverdis., vol.19. 1999; 271-285.

5.     Beasley R.P., Hwang L.Y Overview on the epidemiology of hepatocellular carcinoma. Viral hepatitis and liver disease. 1991; 532-535.

6.     Huo T.I., Lee S.D., Wu J.C. For hepatocellular carcinoma: look for a perfect classification system. J. Hepatol. 20-4; .40(6): 1041-1042.

7.     Barazani Y, Hiatt J.R., Tong M.J. et al. dironic viral hepatitis and hepatocellular carcinoma. World J. Surg. 2007; 31: 1245-250.

8.     Jeong S., Aviata H., Katamura Y Low-dose intermittent interferon - alpha-therapy for HCV - related liver cirrosis after curative treatment of hepatocellular carcinoma. World J. Gastroenterology. 2007;113; 5188-5195.

9.     Zogot S.R., Akberov R.F. Gepatocelljuljarnyj rak (jepidemiologija, luchevaja diagnostika, sovremennye aspekty lechenija). Lekcii dlja vrachej obshhej praktiki, onkologija, prakticheskaja medicina, hirurgija [Hepatocellular cancer (epidemiology, radiodiagnostics, modern aspects of treatment). Lectures for general practice doctors, oncology, practical medicine, surgery]. 2013; 112-115 [In Russ].

10.   Majstrenko N.A., Shejko S.B., Alent'ev A.V. Holangiocelljuljarnyj rak (osobennosti diagnostiki i lechenija) [Cholangiocellular cancer (features of diagnostics and treatment)]. Prakticheskaja onkologija. 2009; 9(4): 229-236 [In Russ].

11.   Ward J., Robinson P. How to detect hepatocellular carcinoma in cirrhosis. Eur. Radiology. 2002; 2258-2273.

12.   Zhang F., Chen X.-P., Zhang W. et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008; 52: 224-232.

13.   Caturelli E., Pompili M. Hemangioma-like lesions in chronic liver disease: diagnostic evaluation in patients. Radiology. 2001; 337-342.

14.   Matsui O., Kadoya M., Kameyama T. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 1991; 493-497.

15.   Xu H.X., Liu G.J., Lu M.D. Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent. J. Clin Ultrasound. 2006; 261-272.

16.   Lencioni R., Piscaglia F. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Journal Of Hepatology. 2008; 48: 848-857.

17.   Prokop M. Spiral and multislice computed tomography of the body. Georg Thieme Verlag. 2003; Р 234-240.

18.   Tiferes D., D’ippolito G. Liver neoplasms: imaging characterization. Radiol. Bras. 2008; 41(2): 119-127.

19.   Medvedeva B.M., Lukjanchenko A.B. Vozmozhnosti MRT v diagnostike gepatocelljuljarnogo raka u pacientov s cirrozom pecheni [Possibilities of MRI in diagnostics of hepatocellular cancer in patients with liver cirrhosis ]. Rejr. 2013; 3(2): 63 [In Russ].

20.   Jeong Y, Yim N., Kang H. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules. Ajr. 2005; 1024-1032.

21.   Lee M.H., Kim S.H., Park M.J., Park C.K. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. Ajr. 2011; 197: 868-875.

22.   Nasu K., Kuroki Y, Tsukamoto T. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. Ajr. 2009; 193: 438-444.

23.   Ferucci J. MRI of the liver. Amer. J. Roentgenol. 1985;147: 1103-1116.

24.   Yamamoto Y, Nishiyama Y Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. The journal of nuclear medicine. 2008; 49(8): 1245-1248.

25.   Hwang K.H., Choi D.-J. Evaluation of patients with hepatocellular carcinomas using [11C]-acetate and [18F]-FDG PET/CT: a preliminary study. Radiation and isotopes. 2009; 67: 1195-1198.

26.   Talbot J., Gutman F. PET/CT in patients with hepatocellular carcinoma using [18F]- fluorocholine: preliminary comparison with [18F]-FDG PET/CT. Eur. J. Nucl. Med. 2006; 33: 1285-1289.

27.   Chang M., Seungmin B. Usefulness of 18F-fluo- rodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. Journal of gastroenterology and hepatology. 2008; 23: 759-765.

28.   Kluge R., Schmidt F., Caca K. Positron emission tomography with [18F]fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001; 33:1029-1035.

29.   Kuang Y, Salem N. Transport and metabolism of radiolabeled choline in hepatocellular carcinoma. Molecularрharmaceutics. 2010; 6: 2077-2092.

30.   Trojan J., Schroeder O., Raedle J. Fluorine-18FDG positron emission tomography for imaging of hepatocellular carcinoma. Am. J. Gastroenterol. 1999; 94: 3314-3319.

31.   Esschert J.W., Bieze M. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT. Eur. J. Nucl. Med. 2011; 38: 436-440.

32.   Lee J., Paeng J. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J. Nucl. Med. 2009; 50: 682-687.

33.   Kuang Y, Salem N. Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11C]-choline: correlation with in vivo metabolic studies. J. Nucl. Med. 2011; 52: 98-106.

34.   Bosman F., Carneiro F., Ruban R. Classification of tumors of the digestive system. 2010; 201-207.